-
Article
Open AccessA perspective on life-cycle health technology assessment and real-world evidence for precision oncology in Canada
Health technology assessment (HTA) can be used to make healthcare systems more equitable and efficient. Advances in precision oncology are challenging conventional thinking about HTA. Precision oncology advanc...
-
Article
Allocating healthcare resources to genomic testing in Canada: latest evidence and current challenges
Precision medicine (PM) informed by next-generation sequencing (NGS) poses challenges for health technology assessment (HTA). To date, there has been limited reimbursement of genomic testing with NGS in Canada...
-
Article
Balancing uncertainty with patient autonomy in precision medicine
By the nature of their unknown pathogenicity, variants of unknown significance (VUS) should not inform clinical decisions for genetic carrier testing; nevertheless, VUS are increasingly returned to patients. W...